Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tonix Pharm Holdings (TNXP)

Tonix Pharm Holdings (TNXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Tonix Pharm Holdings 200 Connell Drive Suite 3100 Berkeley Heights NJ 07928 USA

www.tonixpharma.com Employees: 142 P: 862-799-8599

Sector:

Medical

Description:

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102, for the management of fibromyalgia syndrome and TNX-105 to treat symptoms of post-traumatic stress disorder. Tonix Pharmaceuticals Holding Corp. is headquartered in New York.

Key Statistics

Overview:

Market Capitalization, $K 192,228
Enterprise Value, $K -15,412
Shares Outstanding, K 13,405
Float, K 13,137
% Float 98.00%
Short Interest, K 2,076
Short Float 15.49%
Days to Cover 3.68
Short Volume Ratio 0.43
% of Insider Shareholders 2.00%
% of Institutional Shareholders 82.26%

Financials:

Annual Sales, $ 13,110 K
Annual Net Income, $ -124,020 K
Last Quarter Sales, $ 5,390 K
Last Quarter Net Income, $ -46,910 K
EBIT, $ -125,710 K
EBITDA, $ -123,720 K

Growth:

1-Year Return -9.69%
3-Year Return -99.86%
5-Year Return -100.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -3.98 on 03/12/26
Next Earnings Date 05/11/26 [--]
Earnings Per Share ttm -14.27
EPS Growth vs. Prev Qtr -10.86%
EPS Growth vs. Prev Year 59.26%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-100 on 02/05/25

TNXP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -60.15%
Return-on-Assets % -54.52%
Profit Margin % -946.00%
Debt/Equity 0.00
Price/Sales 14.30
Price/Cash Flow N/A
Price/Book 0.73
Book Value/Share 19.17
Interest Coverage -1,377.00
60-Month Beta 1.75
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.